Skip to Main Content
Table 3.

Biodistribution of EpCAM-targeted immunoliposomes (SIL-Dox) and nontargeted liposomes (SL-Dox) loaded with doxorubicin in mice bearing SW2 tumor xenografts

TissueSIL-Dox (%ID/g)
SL-Dox (%ID/g)
24 h48 h24 h48 h
Blood 11.8 ± 1.7* 1.6 ± 0.5 12.2 ± 0.9 2.6 ± 0.4 
Liver 14.1 ± 0.6 14.5 ± 1.1 12.0 ± 1.3 14.7 ± 1.9 
Spleen 19.3 ± 2.2 22.7 ± 2.1 18.3 ± 1.6 22.0 ± 1.6 
Heart 2.4 ± 0.9 2.6 ± 0.4 1.5 ± 0.1 1.7 ± 0.4 
Lung 2.5 ± 0.8 1.8 ± 0.6 1.4 ± 0.2 1.7 ± 0.3 
Kidney 6.1 ± 1.4 10.3 ± 1.2 6.4 ± 1.5 9.1 ± 1.1 
Tumor 13.0 ± 0.5 15.0 ± 1.0 7.7 ± 0.7 7.1 ± 1.7 
TissueSIL-Dox (%ID/g)
SL-Dox (%ID/g)
24 h48 h24 h48 h
Blood 11.8 ± 1.7* 1.6 ± 0.5 12.2 ± 0.9 2.6 ± 0.4 
Liver 14.1 ± 0.6 14.5 ± 1.1 12.0 ± 1.3 14.7 ± 1.9 
Spleen 19.3 ± 2.2 22.7 ± 2.1 18.3 ± 1.6 22.0 ± 1.6 
Heart 2.4 ± 0.9 2.6 ± 0.4 1.5 ± 0.1 1.7 ± 0.4 
Lung 2.5 ± 0.8 1.8 ± 0.6 1.4 ± 0.2 1.7 ± 0.3 
Kidney 6.1 ± 1.4 10.3 ± 1.2 6.4 ± 1.5 9.1 ± 1.1 
Tumor 13.0 ± 0.5 15.0 ± 1.0 7.7 ± 0.7 7.1 ± 1.7 
*

Values were determined after i.v. injection of [3H]CHE-labeled liposomes. Data represent the mean %ID/g tissue ± SD (n = 3 mice per time point).

P < 0.005, compared with SL-Dox. Statistical significance of the difference between SIL-Dox and SL-Dox was evaluated with a two-tailed, unpaired Student's t test.

Close Modal

or Create an Account

Close Modal
Close Modal